Navigating Global Regulatory Expectations in Outsourced Manufacturing

Key Takeaways

• Outsourcing does not transfer regulatory responsibility. Across FDA guidance, EU GMP requirements, and ICH frameworks, sponsors retain ultimate accountability for product quality and compliance even when manufacturing activities are performed by CDMOs.

• Clear definition of responsibilities is essential. Written contracts and quality agreements establish the operational boundaries between sponsors and manufacturing partners, ensuring that regulated activities, documentation, and oversight responsibilities are explicitly defined.

• Quality agreements function as operational governance tools. Regulators expect quality agreements to serve as working control documents that coordinate communication, change management, investigations, and product disposition across organizations.

• The pharmaceutical quality system extends across organizations. ICH Q10 integrates outsourced activities into the broader pharmaceutical quality system, enabling sponsors and partners to operate within a shared governance structure that supports the full product life cycle.

• Regulatory oversight increasingly reflects global manufacturing networks. Risk-based inspection models and lifecycle change management frameworks require companies to maintain strong governance, documentation, and coordination across distributed manufacturing systems.

Pharmaceutical manufacturing increasingly operates through networks of contract development and manufacturing organizations (CDMOs). Sponsors frequently rely on specialized partners for development, clinical supply, commercial production, packaging, and analytical services. Despite this distributed operating model, regulatory frameworks do not treat outsourced manufacturing as external to the sponsor’s quality responsibilities. Instead, regulators expect outsourced activities to function within the same governance structure that applies to internal operations, with clearly defined interfaces between organizations and well-established mechanisms for oversight and accountability.

U.S. Food and Drug Administration (FDA) guidance on contract manufacturing arrangements makes this expectation explicit. The guidance states that companies engaged in outsourcing should focus on defining, establishing, and documenting manufacturing activities among the parties involved, and it explains that written quality agreements can be used to delineate responsibilities between the product owner and the contract facility in order to support compliance with current good manufacturing practice (CGMP) requirements.¹ These agreements help ensure that each party understands which organization performs specific activities and how information and quality oversight will be coordinated across the relationship.

The same guidance places outsourced work firmly within the broader pharmaceutical quality system (PQS). The FDA notes that contract manufacturing arrangements operate within the larger framework of pharmaceutical quality systems and therefore must be governed through the same structured quality management practices used for internal manufacturing operations. In practical terms, this means that activities performed by a CDMO remain subject to the sponsor’s quality oversight, documentation requirements, and regulatory accountability.

International harmonized guidance reflects the same principle. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline on the PQS describes management of outsourced activities and purchased materials as a core element of an effective quality system.² Rather than treating supply chain partners as independent entities operating outside regulatory governance, the guideline incorporates outsourced work into the lifecycle management structure that supports product development, technology transfer, commercial manufacturing, and post-approval change management.

The combined effect of these frameworks is to establish a consistent regulatory premise: outsourcing manufacturing does not transfer responsibility for product quality or regulatory compliance. Instead, it creates a shared operational environment in which multiple organizations perform defined roles within a single quality governance structure. Sponsors remain accountable for ensuring that the activities performed by their partners are properly controlled, documented, and integrated into the PQS that supports the product throughout its life cycle.

Across global regulatory systems, one of the most consistent expectations governing outsourced pharmaceutical manufacturing is that responsibilities between organizations must be clearly defined, documented, and controlled. Regardless of jurisdiction, regulators treat the interface between a sponsor and a contract manufacturing organization as a formal operational boundary that must be managed through explicit agreements and structured oversight mechanisms.

European Union Good Manufacturing Practice (EU GMP) guidance articulates this principle directly. Chapter 7 states that outsourced activities must be appropriately defined, agreed, and controlled and that a written contract must clearly establish the duties of each party involved in the arrangement.³ The agreement must ensure that both organizations understand their respective responsibilities and that the contract acceptor possesses the competence and capacity required to perform the assigned work.

U.S. regulatory guidance reflects the same expectation through a slightly different framing. FDA guidance on contract manufacturing arrangements explains that written quality agreements can be used to delineate manufacturing activities between the product owner and the contract facility in order to support compliance with CGMP requirements.¹ These agreements provide a structured mechanism for defining how key responsibilities, including manufacturing execution, testing, documentation, and change management, are allocated between organizations.

Although the terminology varies across jurisdictions, the underlying regulatory assumption is consistent: outsourced manufacturing cannot operate through informal coordination or general service contracts alone. Regulators expect clearly articulated operational boundaries that specify which organization performs each regulated activity and how critical information flows between the parties.

While operational activities can be distributed across multiple organizations, regulatory frameworks consistently emphasize that accountability for product quality cannot be transferred through contractual arrangements. The International Council for Harmonisation guideline on GMP for active pharmaceutical ingredients (ICH Q7) makes this principle explicit, stating that consultants or external parties may perform delegated tasks but that ultimate responsibility for API quality must not be delegated.⁴ Technical work may therefore be performed by external organizations, but regulatory accountability remains anchored with the responsible company.

ICH Q7 further reinforces this expectation through the requirement for an independent quality unit within the manufacturing organization. The guideline specifies that the responsibilities of this quality unit, including oversight of quality systems, approval of procedures, review of manufacturing records, and disposition of materials and products, are fundamental to GMP compliance and should not be delegated. This structure ensures that quality oversight remains embedded within the organization responsible for regulatory compliance.

EU GMP guidance reflects the same principle through its approach to batch certification. Chapter 7 requires that when manufacturing activities are outsourced, the pharmaceutical quality system of the contract giver must clearly describe how the Qualified Person responsible for batch certification retains full responsibility for each batch released to the market.³ Even when manufacturing operations are performed by another organization, the Qualified Person remains accountable for confirming that each batch complies with the marketing authorization and applicable GMP requirements.

These frameworks establish a consistent regulatory model for outsourced pharmaceutical manufacturing. Responsibilities for specific activities may be shared between organizations, but accountability for product quality remains anchored with the entity responsible for the product and its release. Clear agreements, defined governance structures, and independent quality oversight therefore serve as the mechanisms that ensure delegated activities remain subject to effective control throughout the supply chain.

While FDA guidance focuses primarily on delineation of CGMP responsibilities between organizations, EU GMP places stronger emphasis on the oversight obligations of the contract giver and the role of the Qualified Person in batch certification. ICH guidelines complement these regional frameworks by defining the lifecycle-based pharmaceutical quality system architecture that integrates outsourced activities into global product governance.

Quality agreements are sometimes perceived primarily as legal documentation that formalizes the relationship between a sponsor and a contract manufacturer. Regulatory guidance, however, treats them less as contractual formalities and more as operational control documents that define how regulatory compliance will function across organizational boundaries. In a distributed manufacturing environment, these agreements serve as the practical mechanism that aligns two independent quality systems around a shared regulatory obligation while also establishing the communication pathways necessary for coordinated oversight.

The FDA describes quality agreements as tools for clarifying how manufacturing responsibilities are divided between the product owner and the contract facility. The guidance explains that such agreements should clearly describe the materials or services to be provided, relevant quality specifications, and the communication mechanisms that will govern interactions between the parties.¹ These provisions help ensure that operational responsibilities, such as manufacturing execution, testing, documentation, investigations, and change control, are understood and consistently managed.

EU GMP Chapter 7 articulates a parallel expectation. The chapter requires written contracts governing outsourced activities that clearly establish the responsibilities and duties of both the contract giver and the contract acceptor.³ The agreement must ensure that each party understands its obligations and that the contract acceptor has the competence and resources necessary to carry out the work in accordance with GMP requirements. In practice, these agreements also establish how the two organizations exchange the information required to maintain compliance and ensure that manufacturing activities are performed according to approved specifications and regulatory commitments.

Within outsourced manufacturing networks, the communication structures embedded in quality agreements become essential elements of compliance governance. Pharmaceutical products often involve multiple manufacturing steps performed across different facilities, and quality oversight frequently requires coordinated action between sponsor and contract partners. Defined communication interfaces ensure that information related to deviations, investigations, change proposals, and product disposition decisions is transmitted in a timely and structured manner.

The International Council for Harmonisation guideline on the PQS provides the most widely recognized framework for structuring this system-level governance. ICH Q10 describes a comprehensive model for an effective PQS designed to support both product life cycle management and regulatory compliance. The guideline outlines a set of management principles and operational elements that integrate development, technology transfer, commercial manufacturing, and continual improvement within a unified quality framework.²

A key aspect of the Q10 model is its explicit recognition that modern pharmaceutical supply chains extend beyond a single organization. The guideline identifies management of outsourced activities and purchased materials as an integral element of the PQS, placing supply chain governance within the core structure of quality management rather than treating it as a separate procurement function.² This inclusion reflects the reality that many critical manufacturing activities are now performed by external partners and that effective quality oversight must extend across organizational boundaries.

Within this framework, the PQS becomes the mechanism that connects internal operations with external partners. Quality agreements, oversight processes, change management procedures, and communication pathways all function as extensions of the sponsor’s quality system, enabling multiple companies to operate within a shared regulatory governance structure. By embedding outsourced activities within the PQS, organizations can maintain consistent control over manufacturing activities even when production and testing are distributed across global networks.

For sponsors and CDMOs operating internationally, this system-level approach provides an important stabilizing effect. Because the ICH Q10 model is designed to complement regional GMP requirements rather than replace them, it allows companies to implement a quality architecture that aligns with multiple regulatory regimes simultaneously while maintaining a consistent internal governance structure for outsourced manufacturing relationships.

Regulatory oversight of pharmaceutical manufacturing increasingly relies on structured risk-based inspection models designed to allocate inspection resources where potential risk to product quality or patient safety is greatest. As pharmaceutical supply chains expand across multiple organizations and geographic regions, regulators have moved toward inspection frameworks that prioritize facilities based on measurable risk indicators rather than relying solely on fixed inspection cycles.

The FDA describes this approach as a risk-based evaluation process used to select both domestic and foreign medical product manufacturing facilities for inspection. Under this model, the agency considers a range of factors to determine where inspection resources should be directed.⁵ The goal is to ensure that regulatory oversight remains focused on facilities and activities that present the highest potential risk.

Within the pharmaceutical sector, inspection prioritization is supported by structured analytical tools. The FDA explains that inspection scheduling and prioritization are based on a risk-based model that evaluates multiple risk factors when determining which facilities should be inspected and how frequently inspections should occur.⁶ These factors can include product characteristics, manufacturing complexity, compliance history, and other indicators that help regulators assess where inspection attention is most needed.

One of the key analytical tools used by the FDA to support this approach is the Site Selection Model (SSM), developed by the agency’s Center for Drug Evaluation and Research (CDER). The SSM is designed to prioritize manufacturing establishments for routine current good manufacturing practice surveillance inspections using a structured risk-based methodology.⁵ Facilities evaluated through this model are ranked according to risk, allowing regulators to focus inspection resources on sites that present higher potential risk to product quality.

These inspection models illustrate how regulatory oversight has evolved in response to increasingly complex global manufacturing networks. Rather than attempting to inspect every facility at fixed intervals, regulators use risk-based systems to focus attention on the sites and activities most likely to affect product quality and patient safety. For companies operating within outsourced manufacturing networks, this approach reinforces the importance of maintaining strong quality systems, transparent documentation, and robust compliance practices across all partner facilities that contribute to the manufacturing process.

Pharmaceutical products continue to evolve throughout their life cycle as companies implement process improvements, respond to supply chain pressures, scale manufacturing capacity, or introduce new manufacturing sites. Managing these post-approval changes within a distributed manufacturing network introduces an additional layer of regulatory complexity, particularly when multiple organizations participate in the manufacturing process.

The ICH guideline on life cycle management addresses this challenge directly. ICH Q12 provides a framework intended to facilitate more predictable and efficient management of post-approval chemistry, manufacturing, and controls (CMC) changes throughout the product life cycle.⁷ The guideline seeks to create a regulatory environment that allows companies to implement improvements and adjustments while maintaining product quality and regulatory compliance.

A central objective of the framework is to support a more structured approach to lifecycle management across global regulatory systems. The guideline explains that harmonized life cycle management practices can enable continual improvement of manufacturing processes, strengthen quality assurance systems, and improve the reliability of medicinal product supply. By providing mechanisms for planning, documenting, and managing manufacturing changes, the framework helps regulators and manufacturers maintain confidence in product quality even as processes evolve.

For outsourced manufacturing networks, life cycle change management requires particularly careful coordination. When multiple organizations contribute to the manufacture of a product, changes implemented at one site can have implications for other sites, quality agreements, regulatory filings, and supply continuity. As a result, effective life cycle management depends on governance systems that allow sponsors and contract partners to manage changes collaboratively while ensuring that regulatory commitments and product quality standards remain fully controlled across the network.

Across FDA guidance, EU GMP requirements, and ICH quality frameworks, expectations for outsourced pharmaceutical manufacturing converge around a consistent set of structural principles. Although the regulatory language differs across jurisdictions, the underlying model for governing distributed manufacturing networks is remarkably aligned. Regulators expect outsourced activities to be defined, controlled, and integrated into a coherent quality governance structure that maintains clear accountability for product quality and regulatory compliance.

In practice, regulatory inspectors increasingly evaluate not only the compliance of individual facilities but also the governance systems that connect sponsors and contract manufacturers across global supply chains.

First, manufacturing responsibilities must be clearly defined and documented. Written agreements, particularly quality agreements and outsourcing contracts, serve as the mechanism through which sponsors and manufacturing partners establish operational boundaries and clarify how regulated activities will be performed and overseen.

Second, accountability for product quality remains anchored with the responsible organization. While operational tasks may be performed by external partners, regulatory frameworks consistently emphasize that ultimate responsibility for product quality and compliance cannot be transferred through contractual arrangements.

Third, outsourced manufacturing must function within a structured PQS. The PQS provides the governance architecture that integrates external manufacturing partners into the sponsor’s life cycle quality framework, ensuring that development, technology transfer, commercial production, and post-approval changes remain under consistent regulatory control.

Finally, regulatory oversight of these distributed networks increasingly relies on risk-based inspection models. Agencies like the FDA use structured risk-based approaches to prioritize inspections of domestic and foreign manufacturing facilities, focusing regulatory attention on sites that present the highest potential risk to product quality and patient safety.

For companies operating across jurisdictions, the practical implication is clear. Regulatory resilience depends not simply on compliance with individual rules within a single regulatory system. Instead, it requires implementation of a governance model capable of meeting the expectations of multiple regulatory authorities simultaneously. Organizations that treat outsourced manufacturing as an integrated quality governance system — rather than a series of transactional service relationships — are better positioned to maintain compliance, manage change across global supply chains, and sustain regulatory confidence in complex manufacturing networks.

1. Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry. U.S. Food and Drug Adminstration. Nov. 2016.

2. ICH Harmonized Tripartite Guideline: Pharmaceutical Quality System Q10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmceuticals for Human Use. 4 Jun. 2008.

3. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use: Chapter 7 Outsourced Activities. European Commission. 38 Jun. 2012.

4. ICH Harmonized Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmceuticals for Human Use. 10 Nov. 2000.

5. “Understanding CDER’s Risk-Based Site Selection Model.” U.S. Food and Drug Administration. 26 Sep. 2018.

6. “Pharmaceutical Inspections and Compliance.” U.S. Food and Drug Administration. 5 Dec. 2024.

7. ICH Harmonised Guideline: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmceuticals for Human Use. 20 Nov. 2019.